AMGN · 10-Q · 2026Q2 · Full report

Capital Expenditures Program

AMGEN INC · 2026-08-05 · Importance 71 · Surprise 82 · In source text

Amgen’s capital expenditures were $1.2 billion in the six months ended June 30, 2026, compared with $780 million in the prior-year period, primarily for new plants and manufacturing-capacity expansion. Management estimates full-year 2026 investments in capital projects of approximately $2.6 billion. The company expects existing funds, operating cash flow and financing access to support working capital, capital expenditures, debt service, dividends, repurchases and strategic acquisitions or licensing activities.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
cashnegativecommitted-2.3%We currently estimate full year 2026 investments in capital projects to be approximately $2.6 billion.
assetspositivecommitted+2.3%We currently estimate full year 2026 investments in capital projects to be approximately $2.6 billion.
cashnegativerealized-1.3%Net cash used in investing activities for six months ended June 30, 2026: $(1,285) million
cashnegativerealized-1.3%Cash used in investing activities during the six months ended June 30, 2026 and 2025 was primarily due to capital expenditures of $1.2…
assetspositiverealized+1.3%Cash used in investing activities during the six months ended June 30, 2026 and 2025 was primarily due to capital expenditures of $1.2…
assetspositiverealizedProperty, plant and equipment, net as of June 30, 2026: $8,547 million and accumulated depreciation and amortization of property, plant…